DK2483389T3 - Stærkt blæredannende Shigella-stammer. - Google Patents

Stærkt blæredannende Shigella-stammer. Download PDF

Info

Publication number
DK2483389T3
DK2483389T3 DK10768559.6T DK10768559T DK2483389T3 DK 2483389 T3 DK2483389 T3 DK 2483389T3 DK 10768559 T DK10768559 T DK 10768559T DK 2483389 T3 DK2483389 T3 DK 2483389T3
Authority
DK
Denmark
Prior art keywords
ala
leu
gly
val
lys
Prior art date
Application number
DK10768559.6T
Other languages
English (en)
Inventor
Christiane Gerke
Scorza Francesco Berlanda
Allan Saul
Luana Maggiore
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK2483389T3 publication Critical patent/DK2483389T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (22)

1. Stærkt blæredannende Shigella-baktene, som udtrykker højst 4 blandt proteinerne TolA, TolB, TolQ, TolR og Pal, og som ikke udtrykker et nativt S/7/ge//a-lipopolysaccharid
2. Bakterie ifølge krav 1, hvor bakterien udtrykker 4 af proteinerne og ikke TolR.
3. Bakterie ifølge krav 1, som ikke udtrykker et TolR-protein.
4. Bakterie ifølge krav 3, som er en Δίο/R-stamme af Shigella.
5. Bakterie ifølge et hvilket som helst af de foregående krav, hvor bakterien ikke udtrykker et nativt S/7/ge//a-0-antigen.
6. Bakterie ifølge et hvilket som helst af de foregående krav, hvor den native lipid A-struktur er ødelagt.
7. Bakterie ifølge et hvilket som helst af de foregående krav, som er en AtolRAmsbB-eller en AtolRAhtrB-stamme.
8. Bakterie ifølge krav 4, hvor stammen er en AtodRAgalU-stamme.
9. Bakterie ifølge et hvilket som helst af de foregående krav, hvor et stxA- og/eller stxB-gen er inaktiveret.
10. Fremgangsmåde til frembringelse af S/7/ge//a-blærer, hvilken fremgangsmåde omfatter trinnet at separere blærerne fra et kulturmedium omfattende en bakterie ifølge et hvilket som helst af kravene 1 til 9, som er blevet dyrket under betingelser, der tillader frigivelse af blærer til mediet fra bakteriens side; eventuelt hvor bakterien er blevet dyrket under jernbegrænsende betingelser.
11. Fremgangsmåde til frembringelse af en stærkt blæredannende Shigella-baktene, hvilken fremgangsmåde omfatter trinnet af modificere et eller flere gener kodende for en eller flere bestanddele af en udgangsbakteries Tol-Pal-system, således at modifikationen foranlediger bakterien, når den dyrkes i kulturmedium, til at frigive større mængder yder-membranblærer til mediet end udgangsbakterien, og hvor modifikationen medfører mutation af en eller flere af udgangsbakteriens tolA-, tolB-, tolQ-, tolR- og/eller pal-gener, og hvor Shigella-bakterien ikke udtrykker et nativt S/i/ge//a-lipopolysaccharid.
12. Blære, der er isoleret eller kan opnås (a) fra en bakterie ifølge et hvilket som helst af kravene 1 til 9, (b) fra en bakterie, der kan opnås ved fremgangsmåden ifølge krav 11, eller (c) ved fremgangsmåden ifølge krav 10.
13. Sammensætning omfattende blærer, som, under dyrkning af en bakterie ifølge et hvilket som helst af kravene 1 til 9 eller opnåeligt ved fremgangsmåden ifølge krav 11, frigives til kulturmediet; eventuelt hvor sammensætningen ikke omfatter nogle levende og/eller hele bakterier.
14. Sammensætning ifølge krav 13, hvor blærerne er til stede i filtratet, der kan opnås efter filtrering gennem et 0,22 μιτι-filter af et kulturmedium, hvori en bakterie ifølge et hvilket som helst af kravene 1 til 9 eller opnåelig ved fremgangsmåden ifølge krav 11 er blevet dyrket.
15. Kulturmedium omfattende bakterier ifølge kravene 1 til 9, eller opnåelige ved fremgangsmåden ifølge krav 11, som er blevet dyrket under betingelser, der tillader frigivelse af blærer til mediet fra bakteriens side.
16. Blære ifølge krav 12 eller sammensætning ifølge krav 13 eller 14 til anvendelse i en fremgangsmåde til rejsning af en antistofreaktion hos et pattedyr, omfattende indgift af blæren eller sammensætningen til pattedyret.
17. Blære ifølge krav 12 eller sammensætning ifølge krav 13 eller 14 til anvendelse i fremstilling af et lægemiddel til forebyggelse af Sb/ge//a-infektion hos et pattedyr.
18. Blære ifølge krav 12 eller sammensætning ifølge krav 13 eller 14 til anvendelse i en fremgangsmåde til beskyttelse af et pattedyr mod Sb/<?e//a-infektion og/eller -sygdom.
19. Blære eller sammensætning ifølge krav 17 eller 18 til anvendelse ifølge krav 17 eller 18, hvor Sb/geWa-infektionen og/eller sygdommen er shigellose, Reiters syndrom og/eller hæmolytisk uræmisyndrom.
20. Blære eller sammensætning ifølge kravene 16 til 19 til anvendelse ifølge kravene 17 til 19, hvor pattedyret er et menneske.
21. Blære ifølge krav 12 eller sammensætning ifølge krav 13 eller 14 til anvendelse som lægemiddel.
22. Blære eller sammensætning ifølge krav 17 eller 21 til anvendelse ifølge kravene 17 eller 21, hvor lægemidlet er en vaccine.
DK10768559.6T 2009-09-28 2010-09-28 Stærkt blæredannende Shigella-stammer. DK2483389T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0917002.8A GB0917002D0 (en) 2009-09-28 2009-09-28 Improved shigella blebs
PCT/IB2010/002582 WO2011036564A2 (en) 2009-09-28 2010-09-28 Hyperblebbing shigella strains

Publications (1)

Publication Number Publication Date
DK2483389T3 true DK2483389T3 (da) 2017-07-10

Family

ID=41350492

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17168855.9T DK3279313T3 (da) 2009-09-28 2010-09-28 Stærkt blæredannende shigella-stammer
DK10768559.6T DK2483389T3 (da) 2009-09-28 2010-09-28 Stærkt blæredannende Shigella-stammer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17168855.9T DK3279313T3 (da) 2009-09-28 2010-09-28 Stærkt blæredannende shigella-stammer

Country Status (21)

Country Link
US (2) US20130052227A1 (da)
EP (2) EP3279313B1 (da)
JP (3) JP2013505716A (da)
KR (1) KR101786025B1 (da)
CN (2) CN107475168A (da)
AU (1) AU2010299577B2 (da)
BR (1) BR112012006912A8 (da)
CA (1) CA2775642C (da)
CY (2) CY1118970T1 (da)
DK (2) DK3279313T3 (da)
ES (2) ES2632747T3 (da)
GB (1) GB0917002D0 (da)
HR (2) HRP20170845T1 (da)
HU (1) HUE053188T2 (da)
LT (2) LT3279313T (da)
NZ (1) NZ599598A (da)
PL (2) PL3279313T3 (da)
PT (2) PT2483389T (da)
SI (2) SI2483389T1 (da)
WO (1) WO2011036564A2 (da)
ZA (1) ZA201202934B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2014076714A2 (en) * 2012-11-19 2014-05-22 Indian Council Of Medical Research Novel immunogenic antigens of shigella
US9636390B2 (en) 2012-11-19 2017-05-02 Indian Council Of Medical Research Immunogenic antigens of shigella
EA033538B1 (ru) 2013-03-15 2019-10-31 Univ Arkansas Композиции и способы усиления иммунного ответа на кишечные патогены
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
CN104974946B (zh) * 2014-04-08 2019-01-11 中国科学院天津工业生物技术研究所 耐高渗透压的重组大肠杆菌及其应用
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
CN107921116A (zh) * 2015-06-16 2018-04-17 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN105647893A (zh) * 2016-03-04 2016-06-08 江南大学 一种D-丙氨酰-D-丙氨酸羧肽酶dacD基因及应用
CN105647892A (zh) * 2016-03-04 2016-06-08 江南大学 一种D-丙氨酰-D-丙氨酸羧肽酶dacA基因及应用
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
US20170360881A1 (en) * 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3263695A1 (en) * 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019163785A1 (ja) * 2018-02-20 2019-08-29 株式会社山田養蜂場本社 膜小胞組成物の製造方法
US20210301297A1 (en) * 2018-07-24 2021-09-30 Wacker Chemie Ag Novel bacterial lpp mutants and the use thereof for the secretory production of recombinant proteins
CN111363018B (zh) * 2020-03-26 2021-10-01 廊坊梅花生物技术开发有限公司 重组菌株及其在l-色氨酸制备中的应用
WO2022133289A2 (en) * 2020-12-18 2022-06-23 Codexis, Inc. Engineered uridine phosphorylase variant enzymes
GB202112149D0 (en) 2021-08-24 2021-10-06 Glaxosmithkline Biologicals Sa Shigellla vaccine
CN113897324B (zh) * 2021-10-13 2023-07-28 云南师范大学 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法
GB202118913D0 (en) 2021-12-23 2022-02-09 Glaxosmithkline Biologicals Sa Method for preparing outer membrane vesicles
CN116855471B (zh) * 2023-09-04 2023-11-28 江苏申基生物科技有限公司 一种嘌呤核苷磷酸化酶突变体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5681736A (en) 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US6759241B1 (en) * 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
PT2255826E (pt) 2002-08-02 2016-06-08 Glaxosmithkline Biologicals Sa Composições de vacina de neisseria compreendendo uma combinação de antigénios
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
AU2012207041A1 (en) 2005-02-18 2012-08-16 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion

Also Published As

Publication number Publication date
ZA201202934B (en) 2012-12-27
SI3279313T1 (sl) 2021-02-26
BR112012006912A8 (pt) 2017-07-11
CY1118970T1 (el) 2018-01-10
AU2010299577A1 (en) 2012-05-24
LT3279313T (lt) 2021-03-25
BR112012006912A2 (pt) 2016-11-22
HUE053188T2 (hu) 2021-06-28
GB0917002D0 (en) 2009-11-11
EP2483389A2 (en) 2012-08-08
WO2011036564A3 (en) 2011-08-04
PL2483389T3 (pl) 2017-09-29
KR20120106729A (ko) 2012-09-26
AU2010299577B2 (en) 2015-09-03
JP2019068864A (ja) 2019-05-09
JP7023248B2 (ja) 2022-02-21
NZ599598A (en) 2013-08-30
JP2013505716A (ja) 2013-02-21
JP2016105736A (ja) 2016-06-16
CN107475168A (zh) 2017-12-15
ES2846901T3 (es) 2021-07-30
LT2483389T (lt) 2017-07-25
PT2483389T (pt) 2017-07-24
EP3279313A2 (en) 2018-02-07
PT3279313T (pt) 2021-01-13
CN102906245A (zh) 2013-01-30
PL3279313T3 (pl) 2021-05-31
US20160289632A1 (en) 2016-10-06
SI2483389T1 (sl) 2017-08-31
EP2483389B1 (en) 2017-05-03
HRP20210243T1 (hr) 2021-04-02
CN102906245B (zh) 2017-08-18
CY1123774T1 (el) 2022-05-27
DK3279313T3 (da) 2021-01-25
EP3279313A3 (en) 2018-03-21
CA2775642C (en) 2022-09-06
CA2775642A1 (en) 2011-03-31
EP3279313B1 (en) 2020-11-25
KR101786025B1 (ko) 2017-10-18
ES2632747T3 (es) 2017-09-15
WO2011036564A2 (en) 2011-03-31
HRP20170845T1 (hr) 2017-08-11
US20130052227A1 (en) 2013-02-28
US11339367B2 (en) 2022-05-24

Similar Documents

Publication Publication Date Title
DK2483389T3 (da) Stærkt blæredannende Shigella-stammer.
EP2482847B1 (en) Purification of bacterial vesicles
BE1022875B1 (fr) Compositions pour une immunisation contre staphylococcus aureus
ITMI20081633A1 (it) Immunogeni di proteine che legano il fattore h.
EP2451833B1 (en) Conserved escherichia coli immunogens
US20130022639A1 (en) Expression of meningococcal fhbp polypeptides
WO2012049662A1 (en) Hyperblebbing salmonella strains
EP3122378B1 (en) Mutant staphylococcal antigens
EP2837386B1 (en) Detoxified Escherichia coli immunogens
AU2013202581A1 (en) Expression of meningococcal fhbp polypeptides